Brain atrophy in healthy aging is related to CSF levels of Aβ1-42.
about
Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's diseaseAre Anxiety Disorders Associated with Accelerated Aging? A Focus on NeuroprogressionThe Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inceptionCSF T-Tau/Aβ42 predicts white matter microstructure in healthy adults at risk for Alzheimer's diseaseThe Alzheimer's disease neuroimaging initiative: progress report and future plansCognitive decline and brain pathology in aging--need for a dimensional, lifespan and systems vulnerability view.2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception.Magnetic resonance imaging in Alzheimer's Disease Neuroimaging Initiative 2Update on the magnetic resonance imaging core of the Alzheimer's disease neuroimaging initiative.Association of gray matter atrophy with age, β-amyloid, and cognition in agingQuantitative structural MRI for early detection of Alzheimer's disease.White matter integrity is associated with cerebrospinal fluid markers of Alzheimer's disease in normal adults.New tools for the study of Alzheimer's disease: what are biomarkers and morphometric markers teaching us?The effects of aging and Alzheimer's disease on cerebral cortical anatomy: specificity and differential relationships with cognitionStructural imaging in early pre-states of dementia.Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal MRI study.Longitudinal MRI atrophy biomarkers: relationship to conversion in the ADNI cohortRelationship between CSF biomarkers of Alzheimer's disease and rates of regional cortical thinning in ADNI data.The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.Role of structural MRI in Alzheimer's diseaseThe aging hippocampus: interactions between exercise, depression, and BDNFShould we disclose amyloid imaging results to cognitively normal individuals?Enrichment and stratification for predementia Alzheimer disease clinical trials.Stroke risk interacts with Alzheimer's disease biomarkers on brain aging outcomes.Cortical gray matter atrophy in healthy aging cannot be explained by undetected incipient cognitive disorders: a comment on Burgmans et al. (2009).Nonlinear registration of longitudinal images and measurement of change in regions of interestAmyloid-β associated cortical thinning in clinically normal elderly.Biomarkers predicting Alzheimer's disease in cognitively normal aging.Brain amyloid-β burden is associated with disruption of intrinsic functional connectivity within the medial temporal lobe in cognitively normal elderlyTemporal evolution of biomarkers and cognitive markers in the asymptomatic, MCI, and dementia stage of Alzheimer's diseaseWhat is normal in normal aging? Effects of aging, amyloid and Alzheimer's disease on the cerebral cortex and the hippocampusSpatially distinct atrophy is linked to β-amyloid and tau in preclinical Alzheimer diseaseEmerging β-amyloid pathology and accelerated cortical atrophy.Hippocampal hyperactivation associated with cortical thinning in Alzheimer's disease signature regions in non-demented elderly adults.Cerebrospinal fluid proteins predict longitudinal hippocampal degeneration in early-stage dementia of the Alzheimer typeFluid biomarkers in Alzheimer disease.Usefulness of DNA Methylation Levels in COASY and SPINT1 Gene Promoter Regions as Biomarkers in Diagnosis of Alzheimer's Disease and Amnestic Mild Cognitive ImpairmentCSF biomarker and PIB-PET-derived beta-amyloid signature predicts metabolic, gray matter, and cognitive changes in nondemented subjects.Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimer's Disease.Biomarkers for the clinical evaluation of the cognitively impaired elderly: amyloid is not enough.
P2860
Q24595802-DBC30D48-CCAD-4907-915C-8E7DAF5FA90AQ26765559-9C6C7E53-12D0-4393-9A04-6FFD61C3805FQ27006831-21C643AB-40C6-46C0-8E7B-6D79F356FE97Q28728773-5F04DD74-7D4A-45A5-96CA-B833F48AC2A1Q28749585-204D62A5-E0D2-43FC-A2A6-DEC82BD30868Q30800136-449BF17C-9536-4B6D-8DE0-1826D61B6F7AQ30971403-31DE1C0A-1589-47C7-9890-86FFC46CA050Q30981669-E4474A79-2EAA-4F7A-8005-340C0DAFF58EQ33572446-72F51AFC-C876-4819-A37A-44A8BE2DFC4CQ33582714-A766E361-9C2F-43E2-B6C9-52A356090B98Q33729033-342D26A7-1891-4817-B63C-A4AD430DDFFBQ33864697-6A4A0F8E-C135-4295-A80B-FC3E9C968D25Q33881726-1A6306FC-4CDA-4992-8B94-0A6ECB39A37BQ33902744-4A74FF1E-B8A6-46B8-9DD3-7A0D636202A3Q33967561-6A23838F-62C3-41FD-9DB8-12BBA82B0B8BQ33987747-0B16B8C5-C590-4EB8-B646-0CB6441DE6DFQ33996059-B37E1952-3A31-4838-9D0F-D13D8A14D745Q34039952-EB9BF933-DC85-417B-9A73-1FD7637AA54BQ34065449-1882FE29-41CF-4934-8B01-C48FEE5CB9B0Q34173192-C90E8123-C796-411C-A62E-A26E374D3024Q34181430-21529300-B142-4BCF-AE7A-137121E4059CQ34286140-B9E0978F-2556-48AD-847E-C96D92159026Q34452239-753313B0-B579-4515-B02C-A75B8E7F6411Q34482685-7385ADD6-85C9-44F2-9D3A-2A723D2DFE27Q34746717-EBB77B5C-3982-4714-B97B-3290EE295D91Q35046222-5EB4AA68-5DCC-4419-81EB-DEEE14A2D9CFQ35053524-572CB347-835C-4456-80A1-FBE2AFB3C1A6Q35091673-32F6EC02-7BAB-49C2-B6ED-9843C3AED412Q35092722-BF9DC702-DEC5-4A1B-97C6-9AF2ABA48CA6Q35106997-323C0959-12E4-407A-8B36-8C12CFD50210Q35129501-8D94860B-CCBC-4F23-9339-792C5343C87CQ35195654-2EAC00D2-2107-4641-950E-DF9F0604857AQ35542164-190191BE-2873-4DAB-89C6-1790A82E5E16Q35787932-ABE67C39-A3CC-41B1-9941-6E418DCDAA7DQ35842864-FCB5D4C7-9D36-4560-9075-C225708DFDD9Q36186513-F62A5A66-96E7-4967-8F8E-4A5DDA9CD29CQ36228525-3B8B60CD-8E03-42E1-AD8F-1141DC41221DQ36407301-2BA2FBDC-6076-4F09-9F9B-69AB5E6C8C1FQ36599172-12FF8154-EDE6-4866-BAE2-593974390376Q36612922-CD8AB371-874F-4112-8741-306BBC3A6C04
P2860
Brain atrophy in healthy aging is related to CSF levels of Aβ1-42.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Brain atrophy in healthy aging is related to CSF levels of Aβ1-42.
@ast
Brain atrophy in healthy aging is related to CSF levels of Aβ1-42.
@en
Brain atrophy in healthy aging is related to CSF levels of Aβ1-42.
@nl
type
label
Brain atrophy in healthy aging is related to CSF levels of Aβ1-42.
@ast
Brain atrophy in healthy aging is related to CSF levels of Aβ1-42.
@en
Brain atrophy in healthy aging is related to CSF levels of Aβ1-42.
@nl
prefLabel
Brain atrophy in healthy aging is related to CSF levels of Aβ1-42.
@ast
Brain atrophy in healthy aging is related to CSF levels of Aβ1-42.
@en
Brain atrophy in healthy aging is related to CSF levels of Aβ1-42.
@nl
P2093
P2860
P50
P356
P1433
P1476
Brain atrophy in healthy aging is related to CSF levels of Aβ1-42.
@en
P2093
Donald J Hagler
James B Brewer
Linda K McEvoy
P2860
P304
P356
10.1093/CERCOR/BHP279
P50
P577
2010-01-04T00:00:00Z